SQZ Biotechnologies Operating Margin 2020-2022 | SQZ

Current and historical operating margin for SQZ Biotechnologies (SQZ) over the last 10 years. The current operating profit margin for SQZ Biotechnologies as of March 31, 2022 is -303.43%.
SQZ Biotechnologies Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2022-03-31 $0.03B $-0.07B -296.00%
2021-12-31 $0.03B $-0.07B -251.85%
2021-09-30 $0.02B $-0.07B -435.29%
2021-06-30 $0.02B $-0.06B -355.56%
2021-03-31 $0.02B $-0.06B -289.47%
2020-12-31 $0.02B $-0.05B -255.00%
2020-06-30 $0.02B $-0.03B -181.25%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00